“epogen” Archives

Entry Author Date Location
FibroGen Pushes Forward With Anemia Pill in China, But Big Test Awaits 01/30/17 San Francisco
ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More 12/06/16 National
As Rival Sputters, FibroGen Heads to Nasdaq Via $146M IPO 11/14/14 San Francisco
What Seattle Needs (Part 2): Dealing With Amgen’s Upcoming Departure 10/07/14 Seattle
How a Little Serendipity Led Acceleron to a Crippling Blood Disease 07/17/14 Boston
Akebia, Trading M&A For an IPO, Follows Fast in Anemia Drug Race 06/09/14 Boston
Assigning Credit and Blame to Biopharma R&D Chiefs 05/29/13 Seattle
Has The Pendulum Swung Too Far in Favor of Rare Diseases? 03/14/13 Seattle
Rescuing Patent-Less Proteins from the Drug Development Dustbin 11/06/12 Seattle
Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen 03/27/12 San Francisco
Affymax Prepares to Mount Challenge to Amgen Anemia Drug Monopoly 01/25/12 San Francisco
Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs 12/19/11 National
Affymax Gears Up for its Make-or-Break Moment, As Anemia Drug Faces FDA Scrutiny 11/17/11 San Francisco
Columbia University’s Tech Transfer Guru, Orin Herskowitz, on Turning IT, Biotech, and Cleantech Ideas Into Businesses 04/04/11 New York
Affymax Hires New CEO, Former Genentecher, to Complete FDA Push With Anemia Drug 01/06/11 San Francisco
AlloCure, With Stem Cell Therapy for Kidney Failure, Arrives in New England with New CEO 07/06/10 Boston
GlycoFi Figures Heavily into Drug Giant Merck’s Follow-on Biologics Plans 04/23/09 Boston
Amgen Scientist, After 13-Year Push, Sees Bone Cancer Work Paying Dividends 10/29/08 Seattle
CMC Icos Sees Expanding Markets for Biotech Drugs With New Factory 10/14/08 Seattle
Amgen’s Dmab Cuts Fracture Risk for Osteoporosis Patients, Just What Investors Wanted to See 09/16/08 Seattle
Amgen Looks to Biomarkers to Boost Its Batting Average in Developing New Drugs 08/07/08 National
Page 1 of 1